T 1634/17 (ADAM6 mice/REGENERON PHARMACEUTICALS) du 25.11.2021
- Identifiant européen de la jurisprudence
- ECLI:EP:BA:2021:T163417.20211125
- Date de la décision
- 25 novembre 2021
- Numéro de l'affaire
- T 1634/17
- Requête en révision de
- -
- Numéro de la demande
- 12716101.6
- Classe de la CIB
- A01K 67/027C07K 16/28C12N 15/85C07K 16/40C07K 16/46C12N 9/64
- Langue de la procédure
- Anglais
- Distribution
- Non distribuées (D)
- Téléchargement
- Décision en anglais
- Versions JO
- Aucun lien JO trouvé
- Autres décisions pour cet affaire
- -
- Résumés pour cette décision
- -
- Titre de la demande
- ADAM6 MICE
- Nom du demandeur
- REGENERON PHARMACEUTICALS, INC.
- Nom de l'opposant
- Kymab Limited
- Chambre
- 3.3.08
- Sommaire
- -
- Dispositions juridiques pertinentes
- European Patent Convention Art 112European Patent Convention Art 113European Patent Convention Art 123(2)European Patent Convention Art 54European Patent Convention Art 56European Patent Convention Art 83European Patent Convention R 103(1)(a)Rules of procedure of the Boards of Appeal 2020 Art 012(3)Rules of procedure of the Boards of Appeal Art 12(4)
- Mots-clés
- Consideration of evidence filed at first instance (yes);
Consideration/admission of evidence filed in appeal (no);
Status of oral/ephemeral disclosure - prior art (no);
Main request - added subject-matter (no);
Main request - sufficiency of disclosure (yes);
Main request - novelty (yes);
Main request - inventive step (yes);
Referral to the Enlarged Board of Appeal (no);
Reimbursement of the appeal fee (no); - Exergue
- -
Order
For these reasons it is decided that:
1. The request of appellant II (opponent) for referral of questions to the Enlarged Board of Appeal is refused.
2. The decision under appeal is set aside.
3. The opposition is rejected.
4. The request of appellant I (patent proprietor) for reimbursement of the appeal fee is refused.